MX2021014015A - Metodos basados en el genoma para reducir el riesgo cardiovascular. - Google Patents
Metodos basados en el genoma para reducir el riesgo cardiovascular.Info
- Publication number
- MX2021014015A MX2021014015A MX2021014015A MX2021014015A MX2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A
- Authority
- MX
- Mexico
- Prior art keywords
- cardiovascular risk
- genome
- based methods
- reduce cardiovascular
- pcsk9 inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biochemistry (AREA)
- Data Mining & Analysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849670P | 2019-05-17 | 2019-05-17 | |
| US201962933181P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/033315 WO2020236670A1 (en) | 2019-05-17 | 2020-05-16 | Genome-based methods for reducing cardiovascular risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014015A true MX2021014015A (es) | 2022-02-21 |
Family
ID=70978651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014015A MX2021014015A (es) | 2019-05-17 | 2020-05-16 | Metodos basados en el genoma para reducir el riesgo cardiovascular. |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12264366B2 (enExample) |
| EP (2) | EP3969620B1 (enExample) |
| JP (2) | JP2022532423A (enExample) |
| CA (1) | CA3139943A1 (enExample) |
| MX (1) | MX2021014015A (enExample) |
| WO (1) | WO2020236670A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230057410A (ko) | 2020-08-25 | 2023-04-28 | 리제너론 파마슈티칼스 인코포레이티드 | Pcsk9 및 ldlr 조절인자를 사용한 패혈증 치료 |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2667894A1 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| JP2010526555A (ja) * | 2007-05-11 | 2010-08-05 | タフツ・メディカル・センター | 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| PT3093663T (pt) | 2008-04-18 | 2018-10-19 | Critical Care Diagnostics Inc | Previsão do risco de eventos cardíacos adversos maiores |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CA2777698A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax1 and ax189 pcsk9 antagonists and variants |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| NZ602220A (en) | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| CA2825778A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| US20130244892A1 (en) * | 2012-02-12 | 2013-09-19 | Aram S. Adourian | Risk Factors and Prediction of Adverse Events |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| AR091462A1 (es) | 2012-06-15 | 2015-02-04 | Genentech Inc | Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso |
| NZ704771A (en) | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| IN2015DN01767A (enExample) | 2012-08-21 | 2015-05-29 | Critical Care Diagnostics Inc | |
| EP2968318A4 (en) | 2013-03-15 | 2016-12-14 | Shifa Biomedical Corp | ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US10329620B2 (en) * | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| US20190017119A1 (en) * | 2017-07-12 | 2019-01-17 | The General Hospital Corporation | Genetic Risk Predictor |
-
2020
- 2020-05-16 EP EP20730885.9A patent/EP3969620B1/en active Active
- 2020-05-16 EP EP25181054.5A patent/EP4640848A3/en active Pending
- 2020-05-16 CA CA3139943A patent/CA3139943A1/en active Pending
- 2020-05-16 JP JP2021568564A patent/JP2022532423A/ja active Pending
- 2020-05-16 MX MX2021014015A patent/MX2021014015A/es unknown
- 2020-05-16 WO PCT/US2020/033315 patent/WO2020236670A1/en not_active Ceased
- 2020-05-16 US US16/876,030 patent/US12264366B2/en active Active
-
2025
- 2025-02-26 US US19/064,447 patent/US20250257406A1/en active Pending
- 2025-12-04 JP JP2025229455A patent/JP2026062658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210002724A1 (en) | 2021-01-07 |
| EP3969620A1 (en) | 2022-03-23 |
| EP4640848A3 (en) | 2026-01-14 |
| US12264366B2 (en) | 2025-04-01 |
| EP3969620B1 (en) | 2025-06-25 |
| JP2026062658A (ja) | 2026-04-10 |
| EP4640848A2 (en) | 2025-10-29 |
| JP2022532423A (ja) | 2022-07-14 |
| US20250257406A1 (en) | 2025-08-14 |
| CA3139943A1 (en) | 2020-11-26 |
| WO2020236670A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003527A2 (pt) | Cianopirrolidinas substituídas com atividade como inibidores de usp30 | |
| CY1123369T1 (el) | Συνθεσεις και μεθοδοι για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α) | |
| MX2022007754A (es) | Nuevos agonistas de il2 y metodos de uso de estos. | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| CL2018000803A1 (es) | Composiciones y métodos para inhibir la expresión génica de lpa. | |
| ECSP21033236A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CY1123367T1 (el) | Μεθοδοι και συνθεσεις για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α) | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CL2024001693A1 (es) | Métodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a. | |
| BR112013020798A2 (pt) | terapia de combinação do inibidor mtor /jak | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2018005925A (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| PH12014501491A1 (en) | Subcutaneous therapeutic use of dpp-4 inhibitor | |
| DOP2015000098A (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
| NZ594365A (en) | Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders | |
| MX373658B (es) | Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2-il)amino-benzoico como inhibidor de quinasa p38. | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| MX363949B (es) | Inhibidor de quinasa. | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| MY201580A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| BR112017017071A2 (pt) | nova lisina descarboxilase, e método para produzir cadaverina utilizando a mesma | |
| NI201700065A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mielopiroxidasa | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 |